

Curriculum Vitae

Name, Title	Stefan Fröhling, Prof. Dr. med.
Position	Managing Director, National Center for Tumor Diseases (NCT) Heidelberg Head, Department of Translational Medical Oncology, German Cancer Research Center (DKFZ)
Research Field	Cancer Genomics Precision Oncology Molecular Pathogenesis and Therapeutic Targeting of Bone and Soft-Tissue Sarcoma and Myeloid Malignancies
Education and Training	
1990-1997	Medical School, Marburg University, Heidelberg University
1999	Doctoral Thesis, Heidelberg University
2004	Postdoctoral Thesis (“Habilitation”), Ulm University
2011	Associate Professor (“Außerplanmäßige Professur”), Ulm University
2019	Full Professor (“W3-Professur für Präzisionsonkologie“), DKFZ and Heidelberg University

Positions and Employment

1998-2005	Resident/Fellow in Internal Medicine, Hematology, Oncology, Rheumatology, Infectious Diseases, Heidelberg University Hospital, Ulm University Hospital
2005-2009	Postdoctoral Fellow, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
2009-2012	Fellow/Attending Physician, Department of Hematology, Oncology, Rheumatology, Infectious Diseases, Ulm University Hospital
2012-2018	Attending Physician, Group Leader, Department of Translational Oncology, NCT Heidelberg, DKFZ, and Heidelberg University Hospital
2018-2020	Acting Managing Director, NCT Heidelberg
2019-present	Head, Department of Translational Medical Oncology, DKFZ
2020-present	Managing Director, NCT Heidelberg

Selected Fellowships and Awards

2004	Leukemia Research Award, Franziska Kolb Foundation
2005-2007	Research Fellowship, German Research Foundation
2009-2011	Young Investigator Fellowship, European Hematology Association-José Carreras Foundation
2018	Uncommon Collaboration Award, Chordoma Foundation

Selected Activities in the Scientific Community

Principal Investigator, MASTER (Molecularly Aided Stratification for Tumor Eradication Research) Program of NCT Heidelberg/Dresden, DKFZ, and the German Cancer Consortium (DKTK) | Coordinator, DKTK Cancer Genome Analysis Platform | Steering Committee Member, German Genomics Initiative (genomDE) | Steering Committee Member, German Cancer Aid (DKH) Network of Oncology Centers of Excellence | Elected Member, Board of the European Hematology Association (EHA) | Member, Cancer Core Europe (CCE) Board of Directors

Selected Recent Publications

- Horak P, ... , Glimm H,* [Fröhling S.](#)* Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers. *Cancer Discov* 11:2780-2795, 2021.
- Koelsche C, ... , [Fröhling S.](#), Pfister SM, von Deimling A. Sarcoma classification by DNA methylation profiling. *Nat Commun* 12:498, 2021.
- Uhrig S, ... , [Fröhling S.](#), Brors B. Accurate and efficient detection of gene fusions from RNA sequencing data. *Genome Res* 31:448-460, 2021.
- Ślabicki M, ... , [Fröhling S.](#), Nowak RP, Fischer ES, Ebert BL. Small-molecule-induced polymerization triggers degradation of BCL6. *Nature* 588:164-168, 2020.
- Jensen P, ... , Scholl C,* [Fröhling S.](#)* Requirement for LIM kinases in acute myeloid leukemia. *Leukemia* 34:3173-3185, 2020.
- Vu T, ... , [Fröhling S.](#), Scholl C, Lane SW. Hematopoietic stem and progenitor cell-restricted Cdx2 expression induces transformation to myelodysplasia and acute leukemia. *Nat Commun* 11:3021, 2020.
- Ślabicki M, ... , [Fröhling S.](#), Golub TR, Fischer ES, Thomä NH, Ebert BL. The CDK inhibitor CR8 mediates cyclin K degradation through the CUL4-RBX1-DDB1 E3 ubiquitin ligase. *Nature* 585:293-297, 2020.
- Voronina N, ... , [Fröhling S.](#), Ernst A. The landscape of chromothripsis across adult cancer types. *Nat Commun* 11:2320, 2020.
- Ronellenfitsch MW, ... , Steinbach JP,* Reuss DE,* Glimm H,* Stenzinger A,* [Fröhling S.](#)* Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors. *J Clin Invest* 130:2488-2495, 2020.
- Gröschel S, ... , Glimm H,* Schlesner M,* [Fröhling S.](#)* Defective homologous recombination DNA repair as therapeutic target in advanced chordoma. *Nat Commun* 10:1635, 2019.
- Heining C, ... , [Fröhling S.](#),* Glimm H.* NRG1 fusions in KRAS wild-type pancreatic cancer. *Cancer Discov* 8:1087-1095, 2018.
- Chudasama P, ... , [Fröhling S.](#) Integrative genomic and transcriptomic analysis of leiomyosarcoma. *Nat Commun* 9:144, 2018.

Full Publication List

<https://www.ncbi.nlm.nih.gov/myncbi/stefan.frohling.1/bibliography/public/>

Biosketch

Stefan Fröhling has been Head of the Division of Translational Medical Oncology at the German Cancer Research Center (DKFZ) since 2019 and Managing Director of the National Center for Tumor Diseases (NCT) Heidelberg since 2020, having held this position on an interim basis since 2018. His work at the interface of applied cancer research and clinical care centers on strategies for multidimensional tumor characterization as a basis for academic clinical trials within the NCT Precision Medicine in Oncology Program, investigating the efficacy of novel, individualized cancer therapies. In addition to his broad activities in the field of cross-entity precision oncology, supported by the European Union (EU), the Federal Ministry of Education and Research (BMBF), the German Research Foundation (DFG), and the German Cancer Aid (DKH), among others, Stefan Fröhling focuses on translating insights into the biology of bone and soft-tissue sarcomas and myeloid malignancies into novel diagnostic and therapeutic strategies. Locally, he directs the NCT Molecular Precision Oncology Program and is deputy spokesperson of the Center for Personalized Medicine (ZPM) Heidelberg; on a national level, he coordinates the Research Platform “Cancer Genome Analysis” of the German Cancer Consortium (DKTK) and the DKFZ/NCT/DKTK MASTER (Molecularly Aided Stratification for Tumor Eradication Research) Program, activities that have paved the way for the widespread implementation of genetically guided precision oncology and its transition into standard care in Germany. Internationally, he is a member of the Board of Directors of Cancer Core Europe (CCE) and has long been active in the European Hematology Association (EHA), including a four-year term as an elected board member. In addition to his scientific and clinical activities, which are characterized by a strong commitment to the involvement of patients as research partners, Stefan Fröhling has a particular interest in the education and training of physician scientists and medical scientists, illustrated by his role in designing the Heidelberg School of Oncology Fellowship Program and as organizer and Chair of the Scientific Committee of the annual CCE Summer School in Translational Cancer Research.